Registered title, quoted from ClinicalTrials.gov
A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
An open trial on primary biliary cholangitis, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 35 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 35
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteAffiliated Hospital of Guangdong Medical University广东医科大学附属医院ZhanjiangHospital page
- Study siteAffiliated Hospital of Qingdao University青岛大学附属医院QingdaoHospital page
- Study siteBaoji People's Hospital宝鸡市人民医院BaojiHospital page
- Study siteBeijing Friendship Hospital首都医科大学附属北京友谊医院BeijingHospital page
- Study siteBeijing Youan Hospital, Capital Medical University首都医科大学附属北京佑安医院BeijingHospital page
- Study siteChina-Japan Friendship Hospital中日友好医院BeijingHospital page
- Study siteChongqing University Three Gorges Hospital重庆大学附属三峡医院ChongqingHospital page
- Study siteFirst Affiliated Hospital of Anhui Medical University安徽医科大学第一附属医院HefeiHospital page
- Study siteFirst Affiliated Hospital of Guangxi Medical University广西医科大学第一附属医院NanningHospital page
- Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
- Study siteFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page
- Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
- Study siteFirst Hospital of China Medical University中国医科大学附属第一医院ShenyangHospital page
- Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
- Study siteFourth Hospital Of Harbin Medical University哈尔滨医科大学第四附属医院HarbinHospital page
- Study siteHangzhou Xixi Hospital杭州市西溪医院HangzhouHospital page
- Study siteHenan Provincial People's Hospital河南省人民医院ZhengzhouHospital page
- Study siteJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page
- Study siteLinyi People's Hospital临沂市人民医院LinyiHospital page
- Study siteMengchao Hepatobiliary Hospital of Fujian Medical University福建医科大学孟超肝胆医院FuzhouHospital page
- Study sitePeking University Shenzhen Hospital北京大学深圳医院ShenzhenHospital page
- Study siteRenji Hospital上海交通大学医学院附属仁济医院ShanghaiHospital page
- Study siteRuijin Hospital上海交通大学医学院附属瑞金医院ShanghaiHospital page
- Study siteSecond Affiliated Hospital of Anhui Medical University安徽医科大学第二附属医院HefeiHospital page
- Study siteSecond Affiliated Hospital of Chongqing Medical University重庆医科大学附属第二医院ChongqingHospital page
- Study siteShenzhen Third People's Hospital深圳市第三人民医院ShenzhenHospital page
- Study siteTaihe Hospital十堰市太和医院ShiyanHospital page
- Study siteTaizhou Hospital, Wenzhou Medical University温州医科大学附属台州医院TaizhouHospital page
- Study siteTianjin First Central Hospital天津市第一中心医院TianjinHospital page
- Study siteTianjin Medical University General Hospital天津医科大学总医院TianjinHospital page
- Study siteTianjin Third Central Hospital天津市第三中心医院TianjinHospital page
- Study siteWest China Hospital四川大学华西医院ChengduHospital page
- Study siteXiamen Hospital厦门市中医院XiamenHospital page
- Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page
- Study siteXinhua Hospital上海交通大学医学院附属新华医院ShanghaiHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07282353, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Documented liver biopsy results consistent with PBC;
Inclusion criterion 6
3 months prior to randomization: obeticholic acid (OCA), azathioprine, colchicine, cyclosporine, methotrexate, mycophenolate, pentoxifylline, systemic corticosteroids and budesonide (˃2 weeks); potentially hepatotoxic drugs (including α-methyl-dopa, sodium valproic acid isoniazid, or nitrofurantoin).
Exclusion criterion 26
12 months prior to randomization: antibodies or immunotherapy directed against ILs or other cytokines or chemokines;
Exclusion criterion 28
Poor blood pressure control is indicated after treatment by a systolic pressure greater than 160 mmHg or diastolic pressure greater than 100 mmHg during screening;
Exclusion criterion 34
History of ALP above 1.0× ULN for at least 6 months
Inclusion criterion 4
ALP ≥1.67× ULN
Inclusion criterion 9
ALT≤5× ULN
Inclusion criterion 10
AST ≤5× ULN
Inclusion criterion 11
TB <2× ULN
Inclusion criterion 12
Estimated glomerular filtration rate (eGFR) > 60mL/min/1.73m2 (calculated by CKD-EPI equation)
Inclusion criterion 13
Platelet count ≥ 1.0× LLN (No thrombocytopenia-related treatment within the past two weeks)
Inclusion criterion 14
White blood cells count (WBC) >3×109/L
Inclusion criterion 16
Absolute neutrophil count (ANC) >1.5×109/L
Inclusion criterion 17
Hemoglobin A1c (HbA1c) ≤9.0%;
Inclusion criterion 18
INR ≤ 1.0× ULN. For participants on anticoagulation therapy, INR must be maintained in the range required for prophylaxis for their specific disease;
Inclusion criterion 19
Advanced PBC as defined by the Rotterdam criteria (albumin<1.0×LLN AND TB >1.0× ULN);
Exclusion criterion 3
Autoimmune hepatitis (AIH) (simplified AIH diagnostic score >6), PBC-AIH overlap syndrome, or overlap with other autoimmune liver diseases
Exclusion criterion 13
Positive HBsAg or positive HCV RNA (tested for in case of known cured HCV infection or positive HCV Ab at screening)
Exclusion criterion 14
Females of reproductive potential must use at least 1 barrier contraceptive and a second effective birth control method during the study and for at least 90 days after the last dose. Male participants who are sexually active with female partners of reproductive potential must use barrier contraception, and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose.
Inclusion criterion 20
Pregnancy, planned pregnancy, lactation;
Exclusion criterion 35
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07282353, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Must have given written informed consent (signed and dated) and any authorizations required by local law;
- When signing ICF age ≥18 years ≤75 years, male or female;
- Meets the diagnostic criteria of PBC, based on any two of the following criteria:
- History of ALP above 1.0× ULN for at least 6 months
- Positive antimitochondrial antibody (AMA) titer (>1:40 on immunofluorescence or M2 positive by ELISA) or positive PBC- specific antinuclear antibody (ANA) (either SP100 or GP210 positive)
- Documented liver biopsy results consistent with PBC;
- UDCA≥6 months before randomization and a stable dose ≥3 months after the efficacy was poor [meeting inclusion criteria (5)a], or UDCA was not tolerated, and stop taking UDCA (no UDCA use for ≥3 months before randomization);
- Laboratory parameters measured at screening period meet the following criteria:
- ALP ≥1.67× ULN
- ALT≤5× ULN
- AST ≤5× ULN
- TB <2× ULN
- Estimated glomerular filtration rate (eGFR) > 60mL/min/1.73m2 (calculated by CKD-EPI equation)
- Platelet count ≥ 1.0× LLN (No thrombocytopenia-related treatment within the past two weeks)
- Albumin> 35g/L
- White blood cells count (WBC) >3×109/L
- Absolute neutrophil count (ANC) >1.5×109/L
- Hemoglobin A1c (HbA1c) ≤9.0%;
- INR ≤ 1.0× ULN. For participants on anticoagulation therapy, INR must be maintained in the range required for prophylaxis for their specific disease;
- Females of reproductive potential must use at least 1 barrier contraceptive and a second effective birth control method during the study and for at least 90 days after the last dose. Male participants who are sexually active with female partners of reproductive potential must use barrier contraception, and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose.
-
Exclusion Criteria:
- Previous exposure to CS0159;
- History of allergy to the CS0159 or its excipients or drugs of similar chemical classes;
- Advanced PBC as defined by the Rotterdam criteria (albumin<1.0×LLN AND TB >1.0× ULN);
- Patients who have had clinically significant complications of hepatic cirrhosis with clinically significant portal hypertension (CSPH), including the following:
- History of liver transplantation, current placement on a liver transplant list, current MELD -Na score ≥ 12;
- History of confirmed esophagogastric variceal bleeding;
- Clinically significant ascites requiring intervention, such as sodium restriction, diuretic therapy, or therapeutic paracentesis;
- Any secondary complications resulting from clinically significant ascites, such as spontaneous bacterial peritonitis, hepatorenal syndrome, or hepatic hydrothorax;
- Hepatic encephalopathy requiring drug therapy;
- Portopulmonary hypertension and/or hepatopulmonary syndrome;
- Hepatocellular carcinoma;
- Other concomitant liver disease including:
- Autoimmune hepatitis (AIH) (simplified AIH diagnostic score >6), PBC-AIH overlap syndrome, or overlap with other autoimmune liver diseases
- Positive HBsAg or positive HCV RNA (tested for in case of known cured HCV infection or positive HCV Ab at screening)
- Primary sclerosing cholangitis (PSC)
- History or clinical evidence of Alcoholic liver disease (ALD)
- Biopsy confirmed Non-alcoholic steatohepatitis (NASH)
- Gilbert's Syndrome
- History or evidence of alpha-1 antitrypsin deficiency
- Liver stiffness measured by transient elastography (TE) > 16.9 Kpa;
- Patient has a positive test for HIV at screening, or active syphilis [defined as positive Treponema pallidum antibody (TP Ab) and a rapid plasma reagin (RPR) card test titer ≥1:8; for low titers (e.g., 1:1 or 1:2), clinical judgment is required to determine if it is active syphilis];
- Administration of the following medications are prohibited as specified below:
- Use of medications, food, and drinks (e.g., grapefruit juice) that are strong or moderate CYP3A4 inhibitors or inducers within 14 days before randomization;
- Use of P-glycoprotein (P-gp) substrate drugs within 14 days before randomization;
- 2 months prior to randomization: fibrates, glitazones, seladelpar and elafibranor.
- 3 months prior to randomization: obeticholic acid (OCA), azathioprine, colchicine, cyclosporine, methotrexate, mycophenolate, pentoxifylline, systemic corticosteroids and budesonide (˃2 weeks); potentially hepatotoxic drugs (including α-methyl-dopa, sodium valproic acid isoniazid, or nitrofurantoin).
- Patients with systemic treatment for pruritus (e.g., with bile acid sequestrants [BAS]) within 3 months prior to randomization.
- 12 months prior to randomization: antibodies or immunotherapy directed against ILs or other cytokines or chemokines;
- Medical conditions that may cause non-hepatic increases in ALP (e.g., paget's disease);
- Patients with severe arrhythmia, or a QTcF interval corrected by Fridericia's formula ≥450 ms (males) or ≥470 ms (females) at screening [Fridericia's formula: QTcF=QT/(RR\^0.33)];
- History or presence of any disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs including bile salt metabolism in the large intestine, eg, inflammatory bowel disease, prior or planned (during the study period) bariatric surgery (such as gastroplasty, roux-en-Y gastric bypass);
- History of malignancy (except for those with a disease-free survival of ≥5 years) or currently under evaluation for malignancy. Except for cases with long-term stable disease and assessed by the investigator as having no significant impact on the trial-such as cured squamous or non-invasive basal cell skin carcinoma, cervical carcinoma in situ, mild to moderate cervical dysplasia, or incidental prostate cancer stage T1a.
- Drug abuse or heavy alcohol use from 12 months prior to randomization throughout the entire clinical study period. Heavy alcohol use is defined as an average weekly alcohol consumption of more than approximately 7 standard drinks for females and more than approximately 14 standard drinks for males. One standard drink is defined as any beverage containing 14g of pure alcohol, such as 12 oz/360 mL of beer (5% alcohol), 8 oz/240 mL of malt liquor (7% alcohol), 5 oz/150 mL of wine (12% alcohol), or 1.5 oz/45 mL of distilled spirits (40% alcohol);
- Poor blood pressure control is indicated after treatment by a systolic pressure greater than 160 mmHg or diastolic pressure greater than 100 mmHg during screening;
- Pregnancy, planned pregnancy, lactation;
- Treatment with any other investigational therapy or device within 30 days or within 5 half-lives, whichever is longer, prior to screening;
- Mental instability or incompetence that may compromise the validity of informed consent or ability to adhere to study requirements;
- Any other condition(s) that would compromise the safety of the patient or compromise the quality of the clinical study, as judged by the investigator.
-
Quoted from ClinicalTrials.gov, NCT07282353, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07282353, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.